Marshall Urist, EVP, Research & Investments at Royalty Pharma plc (RPRX), sold 43,068 shares at $43.05 ($1.9M) on 2022-07-25, disclosed to the SEC on 2022-07-27.
Open-market sale of $1.9M RPRX by EVP, Research & Investments. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $43.05 | 3,600 | $155K | 8.3% |
| 2 | $43.20 | 19,734 | $853K | 45.8% |
| 3 | $43.20 | 19,734 | $853K | 45.8% |
| Total | $43.19 avg | 43,068 | $1.9M | 100% |
| Filing → |
| RPRX | SELL | 2026-07-02 | $508K | — | Filing → |
| RPRX | SELL | 2026-06-25 | $502K | — | Filing → |
| RPRX | SELL | 2026-05-21 | $722K | — | Filing → |